Capricor Announces More Good News For CAP-1002


CureDuchenne provided early and significant funding to Capricor Therapeutics for their Duchenne program, and we are pleased to share their latest updates.  One-year results from their HOPE-2 open label extension study in non-ambulant Duchenne showed significant improvements on the Performance of Upper Limb (PUL version 2.0) for individuals receiving CAP-1002, a type of progenitor cell derived from cardiospheres.  This data builds on the results of the HOPE-2 study, which met its primary endpoint by demonstrating statistically significant improvements in upper limb function at 12 months, and indicates CAP-1002 continues to be a safe and promising experimental therapeutic.  

The HOPE-2 open label extension study remains ongoing, and all participants will continue to be monitored for safety and functional performance. 

Capricor’s Phase 3 trial, HOPE-3, is currently recruiting.  NCT05126758

Read Capricor’s full press release below.

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.